Safety and efficacy of decitabine-primed anti-PD-1 (SHR-1210) treatment in patients with relapsed/refractory classical Hodgkin lymphoma.
2018
7537Background: More than 50% unprecedented objective clinical response rate led to a rapid approval of anti-PD-1 antibodies by FDA using in patients with relapsed/refractory classical Hodgkin lymp...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
2
Citations
NaN
KQI